Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,073 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pyridazine-derived γ-secretase modulators.
Wan Z, Hall A, Jin Y, Xiang JN, Yang E, Eatherton A, Smith B, Yang G, Yu H, Wang J, Ye L, Lau LF, Yang T, Mitchell W, Cai W, Zhang X, Sang Y, Wang Y, Tong Z, Cheng Z, Hussain I, Elliott JD, Matsuoka Y. Wan Z, et al. Among authors: smith b. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4016-9. doi: 10.1016/j.bmcl.2011.04.143. Epub 2011 May 13. Bioorg Med Chem Lett. 2011. PMID: 21636276
Piperidine-derived gamma-secretase modulators.
Hall A, Elliott RL, Giblin GM, Hussain I, Musgrave J, Naylor A, Sasse R, Smith B. Hall A, et al. Among authors: smith b. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1306-11. doi: 10.1016/j.bmcl.2009.08.072. Epub 2009 Aug 23. Bioorg Med Chem Lett. 2010. PMID: 20056541
Pyridine-derived γ-secretase modulators.
Wan Z, Hall A, Sang Y, Xiang JN, Yang E, Smith B, Harrison DC, Yang G, Yu H, Price HS, Wang J, Hawkins J, Lau LF, Johnson MR, Li T, Zhao W, Mitchell WL, Su X, Zhang X, Zhou Y, Jin Y, Tong Z, Cheng Z, Hussain I, Elliott JD, Matsuoka Y. Wan Z, et al. Among authors: smith b. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4832-5. doi: 10.1016/j.bmcl.2011.06.042. Epub 2011 Jun 17. Bioorg Med Chem Lett. 2011. PMID: 21742495
TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I, Harrison DC, Hawkins J, Chapman T, Marshall I, Facci L, Ahmed S, Brackenborough K, Skaper SD, Mead TL, Smith BB, Giblin GM, Hall A, Gonzalez MI, Richardson JC. Hussain I, et al. Among authors: smith bb. Neurodegener Dis. 2011;8(1-2):15-24. doi: 10.1159/000313903. Epub 2010 Aug 4. Neurodegener Dis. 2011. PMID: 20689247
The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase.
Takle AK, Bamford MJ, Davies S, Davis RP, Dean DK, Gaiba A, Irving EA, King FD, Naylor A, Parr CA, Ray AM, Reith AD, Smith BB, Staton PC, Steadman JG, Stean TO, Wilson DM. Takle AK, et al. Among authors: smith bb. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4373-6. doi: 10.1016/j.bmcl.2008.06.070. Epub 2008 Jun 24. Bioorg Med Chem Lett. 2008. PMID: 18621524
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.
Westaway SM, Brown SL, Fell SC, Johnson CN, MacPherson DT, Mitchell DJ, Myatt JW, Stanway SJ, Seal JT, Stemp G, Thompson M, Lawless K, McKay F, Muir AI, Barford JM, Cluff C, Mahmood SR, Matthews KL, Mohamed S, Smith B, Stevens AJ, Bolton VJ, Jarvie EM, Sanger GJ. Westaway SM, et al. Among authors: smith b. J Med Chem. 2009 Feb 26;52(4):1180-9. doi: 10.1021/jm801332q. J Med Chem. 2009. PMID: 19191554
Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptor.
Abberley L, Bebius A, Beswick PJ, Billinton A, Collis KL, Dean DK, Fonfria E, Gleave RJ, Medhurst SJ, Michel AD, Moses AP, Patel S, Roman SA, Scoccitti T, Smith B, Steadman JG, Walter DS. Abberley L, et al. Among authors: smith b. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6370-4. doi: 10.1016/j.bmcl.2010.09.101. Epub 2010 Sep 22. Bioorg Med Chem Lett. 2010. PMID: 20934331
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
12,073 results
You have reached the last available page of results. Please see the User Guide for more information.